Alnylam Pharmaceuticals (ALNY 3.33%), known for its innovative RNA interference (RNAi) therapeutics, released its fourth-quarter earnings on Feb. 13. The company's non-GAAP earnings per share (EPS) came in at $0.06, significantly better than analysts' consensus prediction for a loss of $0.60 per share. Revenue of $593.2 million also outpaced the expected $584 million. This quarter's strong performance was generally fueled by effective product commercialization and strategic execution, despite the complexities Alnylam faced in some market segments.
| Metric | Q4 2024 | Q4 2024 Analysts' Estimate | Q4 2023 | % Change |
|---|---|---|---|---|
| EPS (non-GAAP) | $0.06 | ($0.60) | ($0.77) | N/A |
| Revenue | $593.2 million | $584 million | $439.7 million | 34.9% |
| Net product revenue | $450.8 million | — | $346.3 million | 30.2% |
| Total net income (non-GAAP) | $8.0 million | — | ($96.6 million) | N/A |
Source: Analysts' estimates for the quarter provided by FactSet.
Alnylam Pharmaceuticals: A Quick Overview
Alnylam Pharmaceuticals is a leader in RNA interference (RNAi), a cutting-edge technology that targets RNA to silence genes involved in diseases. It has a strong catalog of approved products and a robust pipeline. It focuses on treatments for rare diseases. Collaborations with industry giants such as Regeneron and Novartis support its commercialization and R&D efforts.
Recently, Alnylam has concentrated on expanding its global market presence and improving its commercial capabilities. It has received multiple approvals for RNAi-based medicines such as Onpattro and Amvuttra, both of which are leading in the company's successful commercialization strategy. Under Alnylam’s strategic plan, which it has dubbed P5x25, it aims to treat more than 500,000 patients worldwide by the end of 2025.
NASDAQ: ALNY
Key Data Points
Quarterly Achievements and Highlights
In the fourth quarter, Alnylam's revenue grew by a substantial 35% year over year to $593.2 million. Net product revenues jumped 30.2% to $450.8 million. The company's transthyretin-mediated amyloidosis franchise, consisting of Onpattro and Amvuttra, accounted for a majority of sales, with $343 million in combined quarterly revenues -- a 35% year-over-year improvement. The company also successfully transitioned a substantial number of patients from Onpattro to the newer Amvuttra.
Additionally, the company's rare disease segment showed strong performance with a 29% increase in yearly revenues, driven by sales of Givlaari and Oxlumo. On the regulatory front, the FDA accepted the company's supplemental New Drug Application for vutrisiran as a treatment for ATTR amyloidosis with cardiomyopathy.
Despite the impressive revenue figures, Alnylam booked an operating loss of $105 million this quarter. That was largely a result of increased spending on research and development (R&D) and selling, general, and administrative (SG&A) costs. Internationally, the company had to manage temporary declines in sales of its transthyretin-mediated amyloidosis treatments due to regulatory net adjustments.
Future Prospects
Management offered an optimistic outlook for 2025, foreseeing total net product revenues in the $2.05 billion to $2.25 billion range. The potential approval and launch of Amvuttra for transthyretin amyloid cardiomyopathy (ATTR-CM) is expected to boost revenues significantly. The company anticipates becoming profitable on a non-GAAP operating income basis.
Moreover, Alnylam plans to scale its global market reach and further expand its pipeline. With more than 25 programs expected to be in the clinical stage by the end of 2025, the company is determined to maintain leadership in RNAi therapeutics. Investors should watch for any regulatory developments or new strategic collaborations.
